Sunshine Heart, Inc. Announces First Patient Implanted in C-Pulse System European Post-Market Study
May 09, 2013 06:00 ET
|
Sunshine Heart
EDEN PRAIRIE, MN--(Marketwired - May 9, 2013) - Sunshine Heart, Inc. (NASDAQ: SSH) announced today the implant of the first patient in the OPTIONS HF C-Pulse System Multicenter Study. The post...
Genetic Technologies Executes Agreement With Nationwide Provider Network
May 03, 2013 06:00 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - May 3, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE), is pleased to advise that it has executed an agreement with Three Rivers Provider...
Genetic Technologies Announces Financial Results for Quarter Ended March 31, 2013
April 30, 2013 16:08 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Apr 30, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Record BREVAGen™ samples received in March quarter,...
Alchemia Announces Multi-Target Drug Discovery Collaboration With AstraZeneca on VAST Discovery Platform
April 23, 2013 05:30 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Apr 23, 2013) - Alchemia Limited (ASX: ACL)
Alchemia is eligible to receive up to $240M in milestones, plus R&D expenses and...
Sunshine Heart, Inc. Closes Public Offering of Common Shares
April 16, 2013 12:55 ET
|
Sunshine Heart
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA--(Marketwired - Apr 16, 2013) - Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) announced today the closing of its previously announced underwritten public...
Sunshine Heart, Inc. Prices $13.1 Million Public Offering of Common Shares
April 11, 2013 09:20 ET
|
Sunshine Heart
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA--(Marketwired - Apr 11, 2013) - Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) announced today the pricing of its previously announced offering of 2,500,000...
Sunshine Heart, Inc. Announces Proposed Public Offering of Common Shares
April 10, 2013 16:37 ET
|
Sunshine Heart
EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA--(Marketwired - Apr 10, 2013) - Sunshine Heart, Inc. (NASDAQ: SSH) (ASX: SHC) announced that it has commenced an underwritten public offering of its common...
Vital Therapies, Inc. rekrutiert ersten Patienten in VTI-208, einer kontrollierten Phase-III-Studie zur Bewertung des ELAD(R)-Systems bei alkoholinduzierter Leberdekompensation
April 04, 2013 17:15 ET
|
Vital Therapies
SAN DIEGO, CA--(Marketwired - Apr 4, 2013) -
Vital Therapies, Inc., ein Unternehmen für Biotechnologie in der Entwicklungsphase mit Schwerpunkt auf der Entwicklung der ersten bioartifiziellen...
Vital Therapies, Inc. inscribe al primer paciente en VTI-208, un ensayo de fase III controlado y aleatorizado que evalúa el sistema ELAD(R) en la descompensación hepática inducida por el alcohol
April 04, 2013 12:17 ET
|
Vital Therapies
SAN DIEGO, CA--(Marketwired - Apr 4, 2013) -
Vital Therapies, Inc., una compañía de biotecnología en fase de desarrollo que se dedica al desarrollo del primer hígado...
IDT Ltd Appoints Dr. Paul MacLeman CEO
April 04, 2013 06:00 ET
|
IDT Australia Ltd
MELBOURNE, AUSTRALIA--(Marketwired - Apr 4, 2013) - IDT Australia Ltd (ASX: IDT) is pleased to announce the appointment of Dr. Paul MacLeman as Chief Executive Officer of the Company, effective...